


PRODUCT: RGB-286638 free base

ALTERNATE NAME: 1-[3-[4-[[4-(2-methoxyethyl)piperazin-1-yl]methyl]phenyl]-4-oxo-1H-indeno[1,2-c]pyrazol-5-yl]-3-morpholin-4-ylurea

CATALOG #: 2886-5, 25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₉H₃₅N₇O₄

MOLECULAR WEIGHT: 545.63

CAS NUMBER: 784210-88-4

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from air and light

DESCRIPTION: RGB-286638 is a potent and selective cyclin-dependent kinase (CDK) inhibitor with IC₅₀ values of 1, 2, 3 and 44 nM for CDK9, CDK1, CDK2, and CDK4, respectively. Less potent against cyclin H-CDK7 and cyclin D3-CDK6. It inhibits cell cycle progression in cancer cells by targeting CDKs, and is also found to induce apoptosis. In a range of pre-clinical models of solid and hematological tumors, RGB-286638 treatment results in tumor regression and increased survival.

REFERENCES: Cirstea, D., *et al.* (2013). *Leukemia* **27**, 2366-2375.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

- Alsterpaullone (Cat. No. 1897-1,5)
- AT-7519 hydrochloride (Cat. No. 2816-5, 25)
- Butyrolactone I (Cat. No. 1690-200)
- Doramapimod (Cat. No. 1954-5, 25)
- Flavopiridol (Cat. No. 2090-1, 5)
- 10Z-Hymenialdisine (Cat. No. 2212-250, 1000)
- Kenpaullone (Cat. No. 1904-1)
- PD1834352 (CI-1040) (Cat. No. 1585-1,5,25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- PD0332991 (Cat. No. 2843-5, 25)
- (R)-Perharidine-1 (Cat. No. 2615-1,5)
- RO-3306 (Cat. No. 2039-1,5)
- Roscovitine (Cat. No. 1950-1,5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- TG003 (Cat. No. 1905-5, 25)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1,5)

USAGE: *FOR RESEARCH CH USE ONLY! Not to be used in humans*